Targeting N-Myristoylation Through NMT2 Prevents Cardiac Hypertrophy And Heart Failure
Overview
Authors
Affiliations
Protein diversity can increase via N-myristoylation, adding myristic acid to an N-terminal glycine residue. In a murine model of pressure overload, knockdown of cardiac N-myristoyltransferase 2 (NMT2) by adeno-associated virus 9 exacerbated cardiac dysfunction, remodeling, and failure. Click chemistry-based quantitative chemical proteomics identified substrate proteins of N-myristoylation in cardiac myocytes. N-myristoylation of MARCKS regulated angiotensin II-induced cardiac pathological hypertrophy by preventing activations of Ca/calmodulin-dependent protein kinase II and histone deacetylase 4 and histone acetylation. Gene transfer of NMT2 to the heart reduced cardiac dysfunction and failure, suggesting targeting N-myristoylation through NMT2 could be a potential therapeutic approach for preventing cardiac remodeling and heart failure.
He S, Li C, Lu M, Lin F, Hu S, Zhang J J Transl Med. 2025; 23(1):17.
PMID: 39762897 PMC: 11702085. DOI: 10.1186/s12967-024-05983-1.
Albert A, Jahan K, Greenberg H, Shamsaldeen Y J Cell Commun Signal. 2024; 18(4):e12052.
PMID: 39691873 PMC: 11647048. DOI: 10.1002/ccs3.12052.
Xiang Y, Tanwar V, Singh P, Follette L, Narayan V, Kapahi P medRxiv. 2024; .
PMID: 39398990 PMC: 11469407. DOI: 10.1101/2024.09.23.24314197.
On Your MARCKS…Get Set…Go: The Race to Explore Myristoylation in HF Is Underway.
Keepers B, Jensen B JACC Basic Transl Sci. 2023; 8(10):1283-1284.
PMID: 38094683 PMC: 10714165. DOI: 10.1016/j.jacbts.2023.08.007.